Regulatory landscape for biosimilars in Latin America is uneven

04/10/2013 | PMLive.com (U.K.)

Economic growth in Latin America has increased the demand for and access to health care services, and government expenditures have risen accordingly, according to World Health Organization data. As complex biologic drugs account for an increasing proportion of spending, payers are looking to biosimilar drugs to contain costs. Despite the pressure, few countries have a clear pathway to biosimilars development and most are approaching the issue with caution.

View Full Article in:

PMLive.com (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA